U.S. and Cuban research institutes are creating the first joint U.S.-Cuban biotech venture. Headquartered in Cuba the new initiative aims to bring new cancer therapies to U.S. patients. The Roswell Park Cancer Institute of Buffalo, New York and Cuba’s Center for Molecular Immunology established the Innovative Immunotherapy Alliance SA after the historic 2014 U.S.-Cuban detente.
U.S. And Cuba Institutes Create First Joint Biotech Venture
New Initiative Aims To Bring New Cancer Therapies To U.S. Patients
U.S. and Cuban research institutes are creating the first joint U.S.-Cuban biotech venture. Headquartered in Cuba the new initiative aims to bring new cancer therapies to U.S. patients.
The Roswell Park Cancer Institute of Buffalo, New York and Cuba’s Center for Molecular Immunology established the Innovative Immunotherapy Alliance SA after the historic 2014 U.S.-Cuban detente. Even though parts of the detente were dismantled this is one of the projects that has been able to continue.
Initial clinical trial results proved to be safe, well tolerated and prime for further study. Roswell Park raised $4 million in donations to fund the CimaVax EGF drug. In addition to the vaccine the alliance is focusing on three more immunotherapy treatments.
For the next few years researchers are studying the safety and efficacy of the treatments with the goal of exporting them to the United States.
Read more at https://www.nbcnews.com/news/latino/u-s-cuban-research-institutes-create-first-joint-biotech-venture-n913476?cid=sm_npd_nn_tw_nw
In addition to bringing our readers stories about education issues in America, we here at Hispanic Outlook feature news articles on topics both related to and outside of the field of education on our website and in our social media.
Renew your subscription to Hispanic Outlook at https://www.hispanicoutlook.com/magazine-online-subscription
